First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection

(European Association for the Study of the Liver) Studies conducted in Italy and Germany confirm the effectiveness and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection, with viral suppression rates similar to those observed in clinical trials.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news